Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB

Molecular and Cellular Biology

Volumn 19, Issue 3, 1999, Pages 1831-1840

  Du, Wei ^a   Lebowitz, Peter F ^a   Prendergast, George C ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYL TRANS TRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHO FACTOR;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0033016719     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.3.1831     Document Type: Article

References (74)

1. Adamson, P., C. J. Marshall, A. Hall, and P. A. Tilbrook. 1992. Posttranslational modification of p21rho proteins. J. Biol. Chem. 267:20033-20038.
2. rho proteins. J. Cell Biol. 119:617-627.
3. Aepfelbacher, M. 1995. ADP-ribosylation of Rho enhances adhesion of U937 cells to fibronectin via the alpha 5 beta 1 integrin receptor. FEBS Lett. 363: 78-80.
4. Barrington, R. E., M. A. Subler, E. Rands, C. A. Omer, P. J. Miller, J. E. Hundley, S. K. Koester, D. A. Troyer, D. J. Bearss, M. W. Conner, J. B. Gibbs, K. Hamilton, K. S. Koblan, S. D. Mosser, T. J. O'Neill, M. D. Schaber, E. T. Senderak, J. J. Windle, A. Oliff, and N. E. Kohl. 1998. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18:85-92.
5. Burridge, K., and M. Chrzanowska-Wodnicka. 1996. Focal adhesions, contractility, and signaling. Annu. Rev. Cell Dev. Biol. 12:463-518.
6. Carmichael, J., W. G. DeGraff, A. F. Gazdar, J. D. Minna, and J. B. Mitchell. 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936-942.
7. Casey, P. J., and M. C. Seabra. 1996. Protein prenyltransferases. J. Biol. Chem. 271:5289-5292.
8. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
9. Cox, A. D. Personal communication.
10. Cox, A. D., and C. J. Der. 1997. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1333:F51-F71.
11. Cox, A. D., A. M. Garcia, J. K. Westwick, J. J. Kowalczyk, M. D. Lewis, D. A. Brenner, and C. J. Der. 1994. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 269:1-4.
12. Cox, A. D., M. M. Hisaka, J. E. Buss, and C. J. Der. 1992. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras function. Mol. Cell. Biol. 12:2606-2615.
13. Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7:546-554.
14. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
15. Engel, M. E., P. K. Datta, and H. L. Moses. 1998. RhoB is stabilized by transforming growth factor β and antagonizes transcriptional activation. J. Biol. Chem. 273:9921-9926.
16. Fritz, G., and B. Kaina. 1997. rhoB encoding a UV-inducible ras-related small GTP-binding protein is regulated by GTPases of the rho family and independent of JNK, ERK, and p38 MAP kinase. J. Biol. Chem. 272:30637-30644.
17. Fritz, G., B. Kaina, and K. Aktories. 1995. The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J. Biol. Chem. 270:25172-25177.
18. Gibbs, J., A. Oliff, and N. E. Kohl. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178.
19. Gibbs, J. B., and A. Oliff. 1997. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 37:143-166.
20. 12]Ras is inhibited by a cytosol-localized Ras mutant. Proc. Natl. Acad. Sci. USA 86: 6630-6634.
21. Hara, M., K. Akasaka, S. Akinaga, M. Okabe, H. Nakano, R. Gomez, D. Wood, M. Uh, and F. Tamanoi. 1993. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90:2281-2285.
22. Harlow, E., and D. Lane (ed.). 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
23. Harper, J. W. 1997. Cyclin-dependent kinase inhibitors. Cancer Surv. 29:91-107.
24. Hotchin, N. A., and A. Hall. 1995. The assembly of integrin adhesion complexes requires both extracellular matrix and intracellular rho/rac GTPases. J. Cell Biol. 131:1857-1865.
25. Hotchin, N. A., and A. Hall. 1996. Regulation of the actin cytoskeleton, integrins and cell growth by the Rho family of small GTPases. Cancer Surv. 27:311-322.
26. Ito, T., S. Kawata, S. Tamura, T. Igura, T. Nagase, J. I. Miyagawa, E. Yamazaki, H. Ishiguro, and Y. Matasuzawa. 1996. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl: protein transferase inhibitor. Jpn. J. Cancer Res. 87:113-116.
27. Jahner, D., and T. Hunter. 1991. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol. Cell. Biol. 11:3682-3690.
28. James, G. L., J. L. Goldstein, and M. S. Brown. 1995. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270:6221-6226.
29. James, G. L., J. L. Goldstein, M. S. Brown, T. E. Rawson, T. C. Somers, R. S. McDowell, C. W. Crowley, B. K. Lucas, A. D. Levinson, and J. C. Marsters. 1993. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260:1937-1942.
30. Kato, K., A. D. Cox, M. M. Hisaka, S. M. Graham, J. E. Buss, and C. J. Der. 1992. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 89:6403-6407.
31. Khosravi-Far, R., P. A. Solski, G. J. Clark, M. S. Kinch, and C. J. Der. 1995. Activation of Racl, RhoA, and mitogen-activated protein kinase are required for Ras transformation. Mol. Cell. Biol. 15:6443-6453.
32. Kohl, N. E., S. D. Mosser, S. J. deSolms, E. A. Giuliani, D. L. Pompliano, S. L. Graham, R. L. Smith, E. M. Scolnick. A. Oliff, and J. B. Gibbs. 1993. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937.
33. Kohl, N. E., C. A. Omer, M. W. Conner, N. J. Anthony, J. P. Davide, S. J. deSolms, E. A. Giuliani, R. P. Gomez, S. L. Graham, K. Hamilton, L. K. Handt, G. D. Hartman, K. S. Koblan, A. M. Kral, P. J. Miller, S. D. Mosser, T. J. O'Neill, E. Rands, M. D. Schaber, J. B. Gibbs, and A. Oliff. 1995. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1:792-797.
34. Kohl, N. E., F. Redner, S. Mosser, E. A. Guiliani, S. J. deSolms, M. W. Conner, N. J. Anthony, W. J. Holtz, R. P. Gomez, T.-J. Lee, R. L. Smith, S. L. Graham, G. D. Hartman, J. Gibbs, and A. Oliff. 1994. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA 91:9141-9145.
35. Lamaze, C., T.-H. Chuang, L. J. Terlecky, G. M. Bokoch, and S. L. Schmid. 1996. Regulation of receptor-mediated endocytosis by Rho and Rac. Nature 382:177-179.
36. Lebowitz, P., P. J. Casey, G. C. Prendergast, and J. Thissen. 1997. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272:15591-15594.
37. Lebowitz, P., W. Du, and G. C. Prendergast. 1997. Prenylation of RhoB is required for its cell transforming functions but not its ability to activate SRE-dependent transcription. J. Biol. Chem. 272:16093-16096.
38. Lebowitz, P., and G. C. Prendergast. 1998. Functional interaction between RhoB and the transcription factor DB1. Cell Adhesion Commun. 4:1-11.
39. Lebowitz, P. F., J. P. Davide, and G. C. Prendergast. 1995. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol. 15:6613-6622.
40. Lebowitz, P. F., and G. C. Prendergast. 1998. Non-Ras targets for farnesyltransferase inhibitors: focus on Rho. Oncogene 17:1439-1445.
41. Lebowitz, P. F., D. Sakamuro, and G. C. Prendergast. 1997. Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment. Cancer Res. 57:708-713.
42. Leonard, D. M. 1997. Ras farnesyltransferase: a new therapeutic target. J. Med. Chem. 40:2971-2990.
43. Lerner, E. C., T. T. Zhang, D. B. Knowles, Y. M. Qian, A. D. Hamilton, and S. M. Sebti. 1997. Inhibition of the prenylation of K-Ras, but not H-or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase-I inhibitor in human tumor cell lines. Oncogene 15:1283-1288.
44. Lin, H.-J., V. Eviner, G. C. Prendergast, and E. White. 1995. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol. 15:4536-4544.
45. Mangues, R., T. Corral, N. E. Kohl, W. F. Symmans, S. Lu, M. Malumbres, J. B. Gibbs, A. Oliff, and A. Pellicer. 1998. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 58:1253-1259.
46. Manne, V., N. Yan, J. M. Carboni, A. V. Tuomari, C. S. Ricca, J. G. Brown, M. L. Andahazy, R. J. Schmidt, D. Patel, R. Zahler, R. Weinmann, C. J. Der, A. D. Cox, J. T. Hunt, E. M. Gordon, M. Barbacid, and B. R. Seizinger. 1995. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 10:1763-1779.
47. Mellor, J., P. Flynn, C. D. Nobes, A. Hall, and P. J. Parker. 1998. PRK1 is targeted to endosomes by the small GTPase, RhoB. J. Biol. Chem. 273:4811-4814.
48. Nagasu, T., K. Yoshimatsu, C. Rowell, M. D. Lewis, and A. M. Garcia. 1995. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res. 55:5310-5314.
49. Olson, M. F., H. F. Paterson, and C. J. Marshall. 1998. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 394: 295-299.
50. Prendergast, G. C. Unpublished observations.
51. Prendergast, G. C., and M. D. Cole. 1989. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Mol. Cell. Biol. 9:124-134.
52. Prendergast, G. C., J. P. Davide, S. J. deSolms, E. Giuliani, S. Graham, J. B. Gibbs, A. Oliff, and N. E. Kohl. 1994. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 14:4193-4202.
53. Prendergast, G. C., R. Khosravi-Far, P. Solski, H. Kurzawa, P. Lebowitz, and C. J. Der. 1995. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10:2289-2296.
54. Qiu, R. G., J. Chen, F. McCormick, and M. Symons. 1995. A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. USA 92:11781-11785.
55. Ridley, A. J., and A. Hall. 1992. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389-399.
56. Rowell, C. A., J. J. Kowalczyk, M. D. Lewis, and A. M. Garcia. 1997. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272:14093-14097.
57. Sakamuro, D., P. Sabbatini, E. White, and G. C. Prendergast. 1997. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887-898.
58. Schmalzing, G., H. P. Richter, A. Hansen, W. Schwarz, I. Just, and K. Aktories. 1995. Involvement of the GTP binding protein Rho in constitutive endocytosis in Xenopus laevis oocytes. J. Cell Biol. 130:1319-1332.
59. Sebti, S. M., and A. D. Hamilton. 1997. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. 74:103-114.
60. Sepp-Lorenzino, L., Z. Ma, E. Rands, N. E. Kohl, J. B. Gibbs, A. Oliff, and N. Rosen. 1995. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:5302-5309.
61. Sepp-Lorenzino, L., and N. Rosen. 1998. A farnesylprotein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J. Biol. Chem. 273:20243-20251.
62. Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602.
63. Shih, T. Y., P. E. Stokes, G. W. Smythers, R. Dhar, and S. Oroszlan. 1982. Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses. J. Biol. Chem. 257:11767-11773.
64. Sun, J., Y. Qian, A. D. Hamilton, and S. M. Sebti. 1998. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473.
65. Sun, J., Y. Qian, A. D. Hamilton, and S. M. Sebti. 1995. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 55:4243-4247.
66. Symons, M. 1996. Rho family GTPases: the cytoskeleton and beyond. Trends Biochem. Sci. 21:178-181.
67. Tapon, N., and A. Hall. 1997. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr. Opin. Cell Biol. 9:86-92.
68. Udagawa, T., and B. W. McIntyre. 1996. ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth. J. Biol. Chem. 271: 12542-12548.
69. Van Aelst, L., and C. D'Souza-Schorey. 1997. Rho GTPases and signaling networks. Genes Dev. 11:2295-2322.
70. Whyte, D. B., P. Kirschmeier, T. N. Hockenberry, I. Nunez-Olivia, L. James, J. J. Catino, W. R. Bishop, and J. K. Pai. 1997. K- and N-ras geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272:14459-14464.
71. Woods, D., D. Parry, H. Cherwinski, E. Bosch, E. Lees, and M. McMahon. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17:5598-5611.
72. Zalcman, G., V. Closson, J. Camonis, N. Honore, M. F. Rousseau-Merck, A. Tavitian, and B. Olofsson. 1996 RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. J. Biol. Chem. 271: 30366-30374.
73. Zalcman, G., V. Closson, G. Linares-Cruz, F. Leregours, N. Honore, A. Tavitian, and B. Olofsson. 1995. Regulation of Ras-related RhoB protein expression during the cell cycle. Oncogene 10:1935-1945.
74. Zhang, F. L., and P. J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:241-269.